Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25C | P30307 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | APEX1 | P27695 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369543 | 0.83 | MEN1 (1.00) | CDC25CMEN1KMT2ATHRBAPEX1 | |
| SCHEMBL1917644 | 0.83 | MEN1 (1.00) | CDC25CMEN1KMT2ATHRBAPEX1 | |
| SCHEMBL9089402 | 0.81 | CDC25C (0.69) | CDC25CMEN1KMT2ATHRBAPEX1 | |
| SCHEMBL1918418 | 0.81 | CDC25C (1.00) | CDC25CMEN1KMT2ATHRBAPEX1 | |
| SCHEMBL18177863 | 0.78 | CDC25C (0.64) | CDC25CMEN1KMT2ACA12CA1 | |
| SCHEMBL5383983 | 0.75 | CDC25C (0.60) | CDC25CMEN1KMT2ACA12CA1 | |
| Hydrochloric Acid SCHEMBL27940290 | 0.74 | CA12 (0.64) | CDC25CMEN1KMT2ATHRBCA12 | |
| SCHEMBL4397361 | 0.73 | CDC25C (0.57) | CDC25C | |
| SCHEMBL4397359 | 0.73 | CDC25C (0.57) | CDC25C | |
| SCHEMBL29362116 | 0.72 | CDC25C (1.00) | CDC25CMEN1KMT2ATHRBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196084-B2 | Cdc25 phosphatase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-27 | — | — | US | claimed |
| US-20060235027-A1 | Inhibitors of cdc25 phosphatases | SCRAS | 2006-10-19 | — | — | US | claimed |
| JP-2004506618-A | — | — | 2004-03-04 | — | — | JP | claimed |
| US-20040034103-A1 | Cdc25 photophatase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-02-19 | — | — | US | claimed |
| EP-1370255-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-12-17 | — | — | EP | claimed |
| WO-2002009686-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2002-02-07 | — | — | WO | claimed |
| EP-2335702-A1 | Product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent | IPSEN PHARMA (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20090253685-A1 | Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFICQUES | 2009-10-08 | — | — | US | disclosed |
| US-20090137596-A1 | G-PROTEIN INHIBITOR | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-05-28 | — | — | US | disclosed |
| EP-1792905-A1 | Product containing at least one phosphatase CDC25 inhibitor combined with at least one other anticancer agent | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2007-06-06 | — | — | EP | disclosed |
| US-7196084-B2 | Cdc25 phosphatase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-27 | — | — | US | disclosed |
| US-20060281736-A1 | Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-12-14 | — | — | US | disclosed |
| US-20060235027-A1 | Inhibitors of cdc25 phosphatases | SCRAS | 2006-10-19 | — | — | US | disclosed |
| EP-1641453-A2 | PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-04-05 | — | — | EP | disclosed |
| EP-1602368-A2 | Cdc25 phosphatase inhibitors | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005000852-A2 | PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2005-01-06 | — | — | WO | disclosed |
| US-20040034103-A1 | Cdc25 photophatase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-02-19 | — | — | US | disclosed |
| EP-1370255-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002009686-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034103-A1 | Cdc25 photophatase inhibitors | CDC25C, CDC25A, CDC25B | CDC25C 1/4885MEN1 3563/4885KMT2A 2705/4885 |
| US-20090137596-A1 | G-PROTEIN INHIBITOR | CDC25A, CDC25C, CDC25B | CDC25C 2/4885MEN1 1031/4885KMT2A 1598/4885 |
| US-20060281736-A1 | Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent | CDC25A, CDC25C, CDC25B | CDC25C 2/4885MEN1 982/4885KMT2A 1461/4885 |
| US-20060235027-A1 | Inhibitors of cdc25 phosphatases | CDC25A, CDC25C, CDC25B | CDC25C 2/4885MEN1 1858/4885KMT2A 1728/4885 |
| US-20090253685-A1 | Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent | CDC25A, CDC25C, CDC25B | CDC25C 2/4885MEN1 954/4885KMT2A 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.